Isolation and characterization of an HIV-1 envelope glycoprotein-specific B-cell from an immortalized human naïve B-cell library

References

1. Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G et al. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog 2011; 7:e1001251 [View Article][PubMed]
   [Google Scholar]
2. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P et al. Broad and potent neutralizing antibodies from an african donor reveal a new HIV-1 vaccine target. Science 2009; 326:285–289 [View Article][PubMed]
   [Google Scholar]
3. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010; 329:856–861 [View Article][PubMed]
   [Google Scholar]
4. Halper-Stromberg A, Lu CL, Klein F, Horwitz JA, Bournazos S et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 2014; 158:989–999 [View Article][PubMed]
   [Google Scholar]
5. Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012; 492:118–122 [View Article][PubMed]
   [Google Scholar]
6. Bar KJ, Sneller MC, Harrison LJ, Justement JS, Overton ET et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N Engl J Med 2016; 375:2037–2050 [View Article][PubMed]
   [Google Scholar]
7. West AP, Scharf L, Scheid JF, Klein F, Bjorkman PJ et al. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell 2014; 156:633–648 [View Article][PubMed]
   [Google Scholar]
8. Hilleman MR. Overview of the needs and realities for developing new and improved vaccines in the 21st century. Intervirology 2002; 45:199–211 [View Article][PubMed]
   [Google Scholar]
9. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010; 17:1055–1065 [View Article][PubMed]
   [Google Scholar]
10. Kwong PD, Mascola JR. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 2012; 37:412–425 [View Article][PubMed]
    [Google Scholar]
11. Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 2010; 467:591–595 [View Article][PubMed]
    [Google Scholar]
12. Haynes BF, Kelsoe G, Harrison SC, Kepler TB. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 2012; 30:423–433 [View Article][PubMed]
    [Google Scholar]
13. Hoot S, Mcguire AT, Cohen KW, Strong RK, Hangartner L et al. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog 2013; 9:e1003106 [Crossref]
    [Google Scholar]
14. Jardine J, Julien JP, Menis S, Ota T, Kalyuzhniy O et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 2013; 340:711–716 [View Article][PubMed]
    [Google Scholar]
15. Yang Z, Li J, Liu Q, Yuan T, Zhang Y et al. Identification of non-HIV immunogens that bind to germline b12 predecessors and prime for elicitation of cross-clade neutralizing HIV-1 antibodies. PLoS One 2015; 10:e0126428 [View Article][PubMed]
    [Google Scholar]
16. Pape KA, Taylor JJ, Maul RW, Gearhart PJ, Jenkins MK. Different B cell populations mediate early and late memory during an endogenous immune response. Science 2011; 331:1203–1207 [View Article][PubMed]
    [Google Scholar]
17. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 2004; 10:871–875 [View Article][PubMed]
    [Google Scholar]
18. Rosén A, Gergely P, Jondal M, Klein G, Britton S. Polyclonal Ig production after Epstein–Barr virus infection of human lymphocytes in vitro. Nature 1977; 267:52–54 [View Article][PubMed]
    [Google Scholar]
19. Liu YJ, Arpin C. Germinal center development. Immunol Rev 1997; 156:111–126 [View Article][PubMed]
    [Google Scholar]
20. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000; 102:553–563 [View Article][PubMed]
    [Google Scholar]
21. Yu X, Tsibane T, Mcgraw PA, House FS, Keefer CJ et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 2008; 455:532–536 [View Article][PubMed]
    [Google Scholar]
22. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 2010; 5:e8805 [View Article][PubMed]
    [Google Scholar]
23. Yuan T, Li J, Zhang MY. A single mutation turns a non-binding germline-like predecessor of broadly neutralizing antibody into a binding antibody to HIV-1 envelope glycoproteins. MAbs 2011; 3:402–407 [View Article][PubMed]
    [Google Scholar]
24. Sun Z, Li J, Hu X, Shao Y, Zhang MY. Reconstitution and characterization of antibody repertoires of HIV-1-infected “elite neutralizers”. Antiviral Res 2015; 118:1–9 [View Article][PubMed]
    [Google Scholar]
25. Dorner M, Zucol F, Berger C, Byland R, Melroe GT et al. Distinct ex vivo susceptibility of B-cell subsets to epstein–barr virus infection according to differentiation status and tissue origin. J Virol 2008; 82:4400–4412 [View Article][PubMed]
    [Google Scholar]